Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...

BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure ...

Healthcare companies are navigating a challenging environment as policy uncertainty and competitive pressures weigh on the ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

The Trump administration is eroding national pandemic flu defenses as it guts health agencies, cuts research and health ...

US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

The chief executive of a speciality chemicals giant which is one of only two Yorkshire-headquartered FTSE 100 constituents has told Insider the 100-year-old business is ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

The fraught discussions playing out between President Donald Trump and one of the world’s most powerful figures could shape ...

Experts say Robert F. Kennedy Jr. has talked about "freedom of choice" in health care while limiting choices on some products for many Americans.